Loading...
Loading...
Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation
CELG, today announced that the European Commission
(EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin
bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine
for first-line treatment of adult patients with metastatic
adenocarcinoma of the pancreas, or metastatic pancreatic cancer.1
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in